- Home
- CWK vs CORT Comparison
CWK vs CORT Comparison
Compare CWK & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CWK | CORT |
|---|---|---|
| Founded | 1784 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.7B |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | CWK | CORT |
|---|---|---|
| Price | $17.03 | $36.38 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 6 |
| Target Price | $18.07 | ★ $111.00 |
| AVG Volume (30 Days) | 1.4M | ★ 3.0M |
| Earning Date | 02-19-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 152.30 | N/A |
| EPS | ★ 0.95 | 0.87 |
| Revenue | ★ $10,003,900,000.00 | $741,172,000.00 |
| Revenue This Year | $8.47 | $21.70 |
| Revenue Next Year | $2.02 | $30.13 |
| P/E Ratio | ★ $17.47 | $40.40 |
| Revenue Growth | 6.77 | ★ 17.92 |
| 52 Week Low | $7.64 | $32.99 |
| 52 Week High | $17.33 | $117.33 |
Technical Indicators
Market Signals| Indicator | CWK | CORT |
|---|---|---|
| Relative Strength Index (RSI) | 57.26 | 24.35 |
| Support Level | $16.33 | $34.06 |
| Resistance Level | $17.21 | $37.48 |
| Average True Range (ATR) | 0.60 | 2.23 |
| MACD | 0.02 | -0.12 |
| Stochastic Oscillator | 81.25 | 58.56 |
Price Performance
Historical ComparisonAbout CWK Cushman & Wakefield plc
Cushman & Wakefield is one of the largest commercial real estate services firms in the world, with global headquarters in Chicago. The firm provides various real estate-related services to owners, occupiers, and investors. These include brokerage services for leasing and capital markets sales as well as advisory services such as valuation, project management, and facilities management.
About CORT Corcept Therapeutics Incorporated
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.